Core support is requested for collection and analysis of blood (serum and lymphocytes) and tumor tissues for each project under the overall program. Procedures will include the following. 1. Centralized collection of blood for serum and lymphocytes, and tumor tissues from JWCI and outside patients. Samples will be processed in a uniform manner which will improve the consistency of lab results. Systems will be established to promote efficient use of materials and to reduce the frequency of venipuncture. (Projects I, II and III). 2. Target antigens will be purified from spent serum-free culture medium, tumor cell extracts and urine of melanoma patients. These procedures are well established and material is required for Projects I and III. 3. Analysis of a large number of serum samples for antibody levels to multiple tumor antigens will be required for each project and will be more efficiently undertaken in a core assay (ELISA and RI?) service. Additionally, T-cell responses monitored by cytokine release (ELISA) will be determined. (Projects I, II, III). 4. Examination of lymphocyte subsets, antigen expression by melanoma cells and antibody binding to tumor cells will be determined by flow cytometry. (projects I, II and III). 5. Elucidation of specific tumor antigen expression and surface phenotype of infiltrating lymphoid cells in tumor biopsy specimens will be examined by immunohistochemical and histological techniques. (Projects I, II and III).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA012582-28
Application #
6101491
Study Section
Project Start
1999-02-01
Project End
2000-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
28
Fiscal Year
1999
Total Cost
Indirect Cost
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Dükel, Muzaffer; Streitfeld, W Scott; Tang, Tsz Ching Chloe et al. (2016) The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia. J Biol Chem 291:21541-21552
Chiu, Connie G; Nakamura, Yoshitaka; Chong, Kelly K et al. (2014) Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60:873-85
Kiyohara, Eiji; Hata, Keisuke; Lam, Stella et al. (2014) Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. Methods Mol Biol 1102:513-22
Greenberg, Edward S; Chong, Kelly K; Huynh, Kelly T et al. (2014) Epigenetic biomarkers in skin cancer. Cancer Lett 342:170-7
Faries, Mark B; Steen, Shawn; Ye, Xing et al. (2013) Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 217:27-34; discussion 34-6
Kidner, Travis B; Morton, Donald L; Lee, Delphine J et al. (2012) Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716-20
Hoshimoto, Sojun; Shingai, Tatsushi; Morton, Donald L et al. (2012) Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26
Hoshimoto, Sojun; Kuo, Christine T; Chong, Kelly K et al. (2012) AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol 132:1689-97
Faries, Mark B; Morton, Donald L (2012) Staging of regional nodes in pulmonary malignancies. Ann Surg Oncol 19:703-5
Hoshimoto, Sojun; Faries, Mark B; Morton, Donald L et al. (2012) Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62

Showing the most recent 10 out of 238 publications